A retrospective study assessing CD34+ cells levels in a series of primary (PMF) and secondary (SMF) MF pts at baseline and during treatment with RUX and identify any possible correlation with response to treatment
Latest Information Update: 10 Aug 2022
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
Most Recent Events
- 10 Aug 2022 New trial record
- 17 Jun 2022 Preliminary results presented at the 27th Congress of the European Haematology Association